TDI-015051

Overview

TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase . TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA . TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS ). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir ( HY-138687 ). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses.The IC 50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the K a value against SARS-CoV-2 is 0.061 nM.

Application

Products | Products > Disease Areas > MERS-CoV Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > DNA Methyltransferase | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-170524
• CAS No.: 3052313-73-9
• Molecular Formula: C22H22FN5O4S
• Molecular Weight: 471.50
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source